{"protocolSection": {"identificationModule": {"nctId": "NCT02322775", "orgStudyIdInfo": {"id": "D3250C00032"}, "secondaryIdInfos": [{"id": "2014-004427-40", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma", "officialTitle": "A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma."}, "statusModule": {"statusVerifiedDate": "2017-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-02-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-10-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-10-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-12-19", "studyFirstSubmitQcDate": "2014-12-19", "studyFirstPostDateStruct": {"date": "2014-12-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-09-29", "resultsFirstSubmitQcDate": "2016-12-21", "resultsFirstPostDateStruct": {"date": "2017-02-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-08-14", "lastUpdatePostDateStruct": {"date": "2017-08-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of benralizumab across the spectrum of asthma disease."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases,"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 211, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm A", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously every 4 weeks", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Arm B", "type": "EXPERIMENTAL", "description": "Placebo administered subcutaneously every 4 weeks", "interventionNames": ["Biological: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab administered subcutaneously every 4 weeks", "armGroupLabels": ["Arm A"]}, {"type": "BIOLOGICAL", "name": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks", "armGroupLabels": ["Arm B"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12", "description": "The FEV1 (L) change from baseline are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect repeated measures (MMRM) analysis with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit (Week 4, Week 8, Week 12), region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline pre-bronchodilator FEV1 (L) as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "timeFrame": "Baseline, Week 4, Week 8 and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12", "description": "The changes from baseline of weekly average of morning PEF (L/min) are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model for repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline morning PEF (L/min) as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12"}, {"measure": "Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12", "description": "The changes from baseline of weekly average of evening PEF (L/min) are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model for repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline evening PEF (L/min) as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12"}, {"measure": "Change From Baseline in Total Asthma Symptom Score at Week 12", "description": "Asthma symptoms were recorded by the patient each morning and evening in the asthma daily diary. Symptoms were recorded using a scale of 0-3, where 0 indicates no asthma symptoms. The daily asthma symptom total score was calculated by taking the sum of the daytime score recorded in the evening and the nighttime score recorded the following morning. The weekly total asthma score was averaged from the daily scores over a 7 day period, with score ranging from 0 to 6, where 0 indicates no asthma symptoms. The changes from baseline of weekly total asthma score are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline total asthma score as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12"}, {"measure": "Change From Baseline in Total Asthma Rescue Medication Use (Puffs) at Week 12", "description": "The number of rescue medication inhalations and nebulizer treatments taken were recorded by the patient in the asthma daily diary twice daily. The number of inhalations (puffs) per day was calculated as \\[number of night inhaler puffs\\] + 2 x \\[number of night nebulizer times\\] + number of day inhaler puffs + 2 x \\[number of day nebulizer times\\]. The changes from baseline in weekly total asthma rescue medication use (puffs) are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline total asthma rescue medication use (puffs) as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12"}, {"measure": "Change From Baseline in Proportion of Nights With Nocturnal Awakenings at Week 12", "description": "Nocturnal awakenings due to asthma symptoms and requiring rescue medication use was recorded by the patient in the asthma daily diary each morning. Proportion of nights with nocturnal awakenings was defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data for awakening due to asthma. The outcome variable for proportion of nights with nocturnal awakenings was the change from baseline at Week 12 in weekly proportion of nights with nocturnal awakenings. The changes are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline proportion of nights with nocturnal awakenings as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12"}, {"measure": "Change From Baseline in Mean ACQ-6 Score at Week 12", "description": "The asthma control questionnaire, ACQ-6, consists of six questions; all assessed on a 7-point scale from 0 to 6, where 0 represents good control and 6 represents poor control. The overall score is the mean of the responses to each of the six questions. The changes from baseline of ACQ-6 score are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit (Week 4, Week 8, Week 12), region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline ACQ-6 score as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "timeFrame": "Baseline, Week 4, Week 8 and Week 12"}, {"measure": "Asthma Exacerbations", "description": "An asthma exacerbation was defined as a worsening of asthma that led to use of systemic corticosteroids for at least 3 days (a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of systemic corticosteroids) or an emergency room or urgent care visit (defined as evaluation and treatment for \\<24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids (as per above) or an inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for \u226524 hours) due to asthma. Number of patients experiencing an event included in the definition of asthma exacerbation was presented.", "timeFrame": "Up to Week 12"}, {"measure": "Change From Baseline in AQLQ(S)+12 Total and Domain Scores at Week 12", "description": "The asthma quality of life questionnaire for 12 years and older, AQLQ(S)+12, consists of 32 questions; all assessed on a 7-point scale from 7 to 1, where 7 represents no impairment and 1 represents severe impairment. The 4 individual domain scores (symptoms, activity limitations, emotional function, and environmental stimuli) are the means of the responses to the questions in each of the domains. The overall score is calculated as the mean response to all questions. The changes from baseline of AQLQ(S)+12 score are compared between benralizumab 30 mg Q4W and placebo by using the analyse of covariance (ANCOVA) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL) and region (Europe or North America) as fixed effects and baseline AQLQ(S)+12 score as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "timeFrame": "Baseline and Week 12"}, {"measure": "Serum Concentrations (ng/mL)", "description": "Blood samples (processed to serum) for pharmacokinetic assessments were collected from all patients at baseline prior to first benralizumab administration at Day 1, at the Week 12 visit or the IP discontinuation visit, and at the Week 20 follow-up visit. Serum concentrations of benralizumab were determined using a validated electrochemiluminescent (ECL) immunoassay.", "timeFrame": "Baseline, Week 12 and Week 20"}, {"measure": "Peripheral Blood Eosinophil Levels", "description": "Peripheral blood eosinophil levels assessments were collected from all patients at baseline prior to first benralizumab administration at Day 1, at the Week 12 visit or the IP discontinuation visit, and at the Week 20 follow-up visit.\n\nChanges at Week 12 (respectively at Week 20) were calculated based on patients with both baseline and Week 12 (respectively Week 20).", "timeFrame": "Baseline, Week 12 and Week 20"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nWritten informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union (EU) guidelines.\n\n* Female and male aged 18 to 75 years, inclusively, at the time of Visit 1.\n* Weight of \u226540 kg.\n* Evidence of asthma as documented by post-bronchodilator (post-BD) reversibility in FEV1 of \u2265 12% demonstrated at Visit 2.\n* Documented use of 1 of the following types of asthma therapy at time of informed consent: Low- to medium-dose ICS (ie, 100 to 500 \u03bcg fluticasone dry powder formulation equivalents total daily dose) with or without other controller medications, eg, an LTRA and/or theophylline or Low-dose ICS/LABA fixed combination therapy (eg, the lowest regular maintenance dose approved in the local country will meet this criterion)\n* Morning pre-bronchodilator (pre-BD) FEV1 of \\> 50% to \u2264 90% predicted at Visit 2.\n\nExclusion Criteria:\n\n* Clinically important pulmonary disease other than asthma (eg, active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).\n* Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:\n* Affect the safety of the patient throughout the study\n* nfluence the findings of the studies or their interpretations,- Impede the patient's ability to complete the entire duration of study.\n* Known history of allergy or reaction to the investigational product formulation.\n* History of anaphylaxis to any biologic therapy.- History of Guillain-Barr\u00e9 syndrome.\n* A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy.- Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period.\n* Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study.\n* Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll.\n* A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.\n* History of cancer:\n* Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained.\n* Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Gary T. Ferguson, M.D.,P.C.", "affiliation": "Pulmonary Research Institute of Southeast Michigan", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Research Site", "city": "Clearwater", "state": "Florida", "zip": "33756", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32825", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Blue Island", "state": "Illinois", "zip": "60406", "country": "United States", "geoPoint": {"lat": 41.65726, "lon": -87.68005}}, {"facility": "Research Site", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Research Site", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Research Site", "city": "Monroe", "state": "North Carolina", "zip": "28112", "country": "United States", "geoPoint": {"lat": 34.98543, "lon": -80.54951}}, {"facility": "Research Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Grove City", "state": "Ohio", "zip": "43123", "country": "United States", "geoPoint": {"lat": 39.88145, "lon": -83.09296}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Ajax", "state": "Ontario", "zip": "L1Z 0M1", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Research Site", "city": "Burlington", "state": "Ontario", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "zip": "L9C 2Y6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K2H 8T5", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "zip": "M9C 4Z5", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "St Charles Borromee", "state": "Quebec", "zip": "J6E 2B4", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -73.46586}}, {"facility": "Research Site", "city": "Trois Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1G 3Y8", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Bamberg", "zip": "96049", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "Research Site", "city": "Berlin", "zip": "10787", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Frankfurt/Main", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Hannover", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Neu-Isenburg", "zip": "63263", "country": "Germany", "geoPoint": {"lat": 50.04832, "lon": 8.69406}}, {"facility": "Research Site", "city": "Balassagyarmat", "zip": "2660", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Research Site", "city": "Kom\u00e1rom", "zip": "2900", "country": "Hungary", "geoPoint": {"lat": 47.74318, "lon": 18.11913}}, {"facility": "Research Site", "city": "Miskolc", "zip": "3529", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "Research Site", "city": "P\u00e9cs", "zip": "7626", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"facility": "Research Site", "city": "P\u00e9cs", "zip": "7635", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"facility": "Research Site", "city": "Sz\u00e1zhalombatta", "zip": "2440", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Research Site", "city": "Katowice", "zip": "40-954", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Research Site", "city": "Mr\u0105gowo", "zip": "11-700", "country": "Poland", "geoPoint": {"lat": 53.86437, "lon": 21.30507}}, {"facility": "Research Site", "city": "Ostr\u00f3w Wielkopolski", "zip": "63-400", "country": "Poland", "geoPoint": {"lat": 51.65501, "lon": 17.80686}}, {"facility": "Research Site", "city": "Pabianice", "zip": "95-200", "country": "Poland", "geoPoint": {"lat": 51.66446, "lon": 19.35473}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-693", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-823", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Tarn\u00f3w", "zip": "33-100", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "51-162", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "53-301", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Bratislava", "zip": "821 06", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Research Site", "city": "Bratislava", "zip": "851 01", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Research Site", "city": "Humenne", "zip": "066 01", "country": "Slovakia", "geoPoint": {"lat": 48.93707, "lon": 21.91625}}, {"facility": "Research Site", "city": "Kosice", "zip": "040 01", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Research Site", "city": "Levice", "zip": "934 01", "country": "Slovakia", "geoPoint": {"lat": 48.21563, "lon": 18.60705}}, {"facility": "Research Site", "city": "Poprad", "zip": "058 01", "country": "Slovakia", "geoPoint": {"lat": 49.06144, "lon": 20.29798}}, {"facility": "Research Site", "city": "Presov", "zip": "081 81", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"facility": "Research Site", "city": "Vrable", "zip": "952 01", "country": "Slovakia", "geoPoint": {"lat": 48.24371, "lon": 18.30846}}, {"facility": "Research Site", "city": "Zilina", "zip": "010 01", "country": "Slovakia", "geoPoint": {"lat": 49.22315, "lon": 18.73941}}]}, "referencesModule": {"references": [{"pmid": "28545978", "type": "BACKGROUND", "citation": "Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017 Jul;5(7):568-576. doi: 10.1016/S2213-2600(17)30190-X. Epub 2017 May 22."}], "seeAlsoLinks": [{"label": "CSP redacted", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3365&filename=ClinicalStudyProtocol_BISE_redacted.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Eligible adult patients were stratified by baseline blood eosinophil count (\\<300 cells/\u03bcL or \u2265300 cells/\u03bcL) and by region (USA versus Rest of the World per the IVRS). Patients were then randomized to either benralizumab 30 mg Q4W or placebo in a 1:1 ratio.", "recruitmentDetails": "After enrollment, eligible patients entered a 2- to 4-week screening/run-in period and were converted to budesonide dry powder inhaler twice daily for the duration of the study.\n\nPatients who continued to meet eligibility criteria at the end of the run-in period entered a 12 weeks double-blind treatment period followed by two follow-up visits.", "groups": [{"id": "FG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "FG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "106"}, {"groupId": "FG001", "numSubjects": "105"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "101"}, {"groupId": "FG001", "numSubjects": "99"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Not willing to perform all FU visits", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "BG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "106"}, {"groupId": "BG001", "value": "105"}, {"groupId": "BG002", "value": "211"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "48.3", "spread": "14.40"}, {"groupId": "BG001", "value": "51.1", "spread": "12.60"}, {"groupId": "BG002", "value": "49.7", "spread": "13.58"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": ">=18-<50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "93"}]}]}, {"title": ">=50-<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "89"}]}]}, {"title": ">=65-<=75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "29"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "129"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "82"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "197"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "9"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "100"}, {"groupId": "BG001", "value": "102"}, {"groupId": "BG002", "value": "202"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12", "description": "The FEV1 (L) change from baseline are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect repeated measures (MMRM) analysis with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit (Week 4, Week 8, Week 12), region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline pre-bronchodilator FEV1 (L) as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litre", "timeFrame": "Baseline, Week 4, Week 8 and Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.248", "spread": "0.6062"}, {"groupId": "OG001", "value": "2.246", "spread": "0.7677"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.310", "spread": "0.6702"}, {"groupId": "OG001", "value": "2.261", "spread": "0.7959"}]}]}, {"title": "Change from baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.057", "spread": "0.2734"}, {"groupId": "OG001", "value": "-0.016", "spread": "0.2350"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null hypothesis was: H0: Change from baseline in pre-bronchodilator FEV1 (L) at Week 12 (benralizumab vs placebo)=0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.040", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "Mixed Models Analysis", "paramType": "Difference of Least Square Means", "paramValue": "0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "0.15"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12", "description": "The changes from baseline of weekly average of morning PEF (L/min) are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model for repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline morning PEF (L/min) as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "307.413", "spread": "95.9467"}, {"groupId": "OG001", "value": "308.226", "spread": "113.5895"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "311.041", "spread": "101.8169"}, {"groupId": "OG001", "value": "304.037", "spread": "113.2538"}]}]}, {"title": "Change from baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.675", "spread": "56.5182"}, {"groupId": "OG001", "value": "-6.196", "spread": "45.3077"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.233", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "Mixed Models Analysis", "paramType": "Difference of Least Square Means", "paramValue": "8.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.74", "ciUpperLimit": "23.42"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12", "description": "The changes from baseline of weekly average of evening PEF (L/min) are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model for repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline evening PEF (L/min) as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "326.948", "spread": "97.4034"}, {"groupId": "OG001", "value": "316.743", "spread": "116.6919"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "330.719", "spread": "106.7579"}, {"groupId": "OG001", "value": "316.047", "spread": "118.7000"}]}]}, {"title": "Change from baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.361", "spread": "51.9979"}, {"groupId": "OG001", "value": "-2.956", "spread": "47.9136"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.456", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "Mixed Models Analysis", "paramType": "Difference of Least Square Means", "paramValue": "5.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.67", "ciUpperLimit": "19.25"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Asthma Symptom Score at Week 12", "description": "Asthma symptoms were recorded by the patient each morning and evening in the asthma daily diary. Symptoms were recorded using a scale of 0-3, where 0 indicates no asthma symptoms. The daily asthma symptom total score was calculated by taking the sum of the daytime score recorded in the evening and the nighttime score recorded the following morning. The weekly total asthma score was averaged from the daily scores over a 7 day period, with score ranging from 0 to 6, where 0 indicates no asthma symptoms. The changes from baseline of weekly total asthma score are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline total asthma score as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.934", "spread": "0.9310"}, {"groupId": "OG001", "value": "1.952", "spread": "1.0375"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.326", "spread": "1.0448"}, {"groupId": "OG001", "value": "1.541", "spread": "1.1208"}]}]}, {"title": "Change from baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.567", "spread": "0.7875"}, {"groupId": "OG001", "value": "-0.420", "spread": "0.8767"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.266", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "Mixed Models Analysis", "paramType": "Difference of Least Square Means", "paramValue": "-0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.35", "ciUpperLimit": "0.10"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Asthma Rescue Medication Use (Puffs) at Week 12", "description": "The number of rescue medication inhalations and nebulizer treatments taken were recorded by the patient in the asthma daily diary twice daily. The number of inhalations (puffs) per day was calculated as \\[number of night inhaler puffs\\] + 2 x \\[number of night nebulizer times\\] + number of day inhaler puffs + 2 x \\[number of day nebulizer times\\]. The changes from baseline in weekly total asthma rescue medication use (puffs) are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline total asthma rescue medication use (puffs) as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs per day", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.953", "spread": "3.0794"}, {"groupId": "OG001", "value": "2.641", "spread": "3.0671"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.647", "spread": "2.4782"}, {"groupId": "OG001", "value": "2.070", "spread": "2.6848"}]}]}, {"title": "Change from baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.098", "spread": "2.3588"}, {"groupId": "OG001", "value": "-0.665", "spread": "2.2744"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.200", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "Mixed Models Analysis", "paramType": "Difference of Least Square Means", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.91", "ciUpperLimit": "0.19"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Proportion of Nights With Nocturnal Awakenings at Week 12", "description": "Nocturnal awakenings due to asthma symptoms and requiring rescue medication use was recorded by the patient in the asthma daily diary each morning. Proportion of nights with nocturnal awakenings was defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data for awakening due to asthma. The outcome variable for proportion of nights with nocturnal awakenings was the change from baseline at Week 12 in weekly proportion of nights with nocturnal awakenings. The changes are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect model repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit, region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline proportion of nights with nocturnal awakenings as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Proportion of nights", "timeFrame": "Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11 and Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.246", "spread": "0.2924"}, {"groupId": "OG001", "value": "0.279", "spread": "0.3326"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.086", "spread": "0.2003"}, {"groupId": "OG001", "value": "0.144", "spread": "0.2796"}]}]}, {"title": "Change from baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.158", "spread": "0.2515"}, {"groupId": "OG001", "value": "-0.139", "spread": "0.2659"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.380", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "Mixed Models Analysis", "paramType": "Difference of Least Square Means", "paramValue": "-0.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.08", "ciUpperLimit": "0.03"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean ACQ-6 Score at Week 12", "description": "The asthma control questionnaire, ACQ-6, consists of six questions; all assessed on a 7-point scale from 0 to 6, where 0 represents good control and 6 represents poor control. The overall score is the mean of the responses to each of the six questions. The changes from baseline of ACQ-6 score are compared between benralizumab 30 mg Q4W and placebo by using the mixed-effect repeated measures (MMRM) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL), protocol specified visit (Week 4, Week 8, Week 12), region (Europe or North America) and treatment\\*visit interaction as fixed effects and baseline ACQ-6 score as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline, Week 4, Week 8 and Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.119", "spread": "0.8423"}, {"groupId": "OG001", "value": "2.092", "spread": "0.8975"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.428", "spread": "0.8621"}, {"groupId": "OG001", "value": "1.568", "spread": "1.0090"}]}]}, {"title": "Change from baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.714", "spread": "0.8700"}, {"groupId": "OG001", "value": "-0.495", "spread": "0.7908"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.114", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "Mixed Models Analysis", "paramType": "Difference of Least Square Means", "paramValue": "-0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.39", "ciUpperLimit": "0.04"}]}, {"type": "SECONDARY", "title": "Asthma Exacerbations", "description": "An asthma exacerbation was defined as a worsening of asthma that led to use of systemic corticosteroids for at least 3 days (a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of systemic corticosteroids) or an emergency room or urgent care visit (defined as evaluation and treatment for \\<24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids (as per above) or an inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for \u226524 hours) due to asthma. Number of patients experiencing an event included in the definition of asthma exacerbation was presented.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients per number of exacerbations", "timeFrame": "Up to Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "0 exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "103"}]}]}, {"title": "1 exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "2 exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in AQLQ(S)+12 Total and Domain Scores at Week 12", "description": "The asthma quality of life questionnaire for 12 years and older, AQLQ(S)+12, consists of 32 questions; all assessed on a 7-point scale from 7 to 1, where 7 represents no impairment and 1 represents severe impairment. The 4 individual domain scores (symptoms, activity limitations, emotional function, and environmental stimuli) are the means of the responses to the questions in each of the domains. The overall score is calculated as the mean response to all questions. The changes from baseline of AQLQ(S)+12 score are compared between benralizumab 30 mg Q4W and placebo by using the analyse of covariance (ANCOVA) with baseline blood eosinophil count (\u2265300 cells/\u03bcL or \\<300 cells/\u03bcL) and region (Europe or North America) as fixed effects and baseline AQLQ(S)+12 score as a covariate.\n\nChanges at Week 12 were calculated based on patients with both baseline and Week 12.", "populationDescription": "The Full Analysis Set comprised all patients randomised and receiving any investigational product (IP), irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Total score - Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.825", "spread": "0.9787"}, {"groupId": "OG001", "value": "4.895", "spread": "1.0339"}]}]}, {"title": "Total score - W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.415", "spread": "0.9478"}, {"groupId": "OG001", "value": "5.284", "spread": "1.0851"}]}]}, {"title": "Total score - CFB at W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.585", "spread": "0.8675"}, {"groupId": "OG001", "value": "0.357", "spread": "0.7979"}]}]}, {"title": "Symptoms score - Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.649", "spread": "1.0367"}, {"groupId": "OG001", "value": "4.692", "spread": "1.0830"}]}]}, {"title": "Symptoms score - W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.380", "spread": "1.0076"}, {"groupId": "OG001", "value": "5.212", "spread": "1.1373"}]}]}, {"title": "Symptoms score - CFB at W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.727", "spread": "0.9890"}, {"groupId": "OG001", "value": "0.483", "spread": "0.9243"}]}]}, {"title": "Activity limitations score - Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.017", "spread": "1.0029"}, {"groupId": "OG001", "value": "5.048", "spread": "1.0277"}]}]}, {"title": "Activity limitations score - W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.503", "spread": "0.9672"}, {"groupId": "OG001", "value": "5.343", "spread": "1.0803"}]}]}, {"title": "Activity limitations score - CFB at W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.481", "spread": "0.8156"}, {"groupId": "OG001", "value": "0.275", "spread": "0.8105"}]}]}, {"title": "Emotional function score - Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.95", "spread": "1.277"}, {"groupId": "OG001", "value": "5.04", "spread": "1.373"}]}]}, {"title": "Emotional function score - W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.54", "spread": "1.215"}, {"groupId": "OG001", "value": "5.45", "spread": "1.307"}]}]}, {"title": "Emotional function score - CFB at W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.57", "spread": "1.094"}, {"groupId": "OG001", "value": "0.35", "spread": "1.014"}]}]}, {"title": "Environmental stimuli score - Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.658", "spread": "1.3320"}, {"groupId": "OG001", "value": "4.905", "spread": "1.3554"}]}]}, {"title": "Environmental stimuli score - W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.120", "spread": "1.2910"}, {"groupId": "OG001", "value": "5.130", "spread": "1.3372"}]}]}, {"title": "Environmental stimuli score - CFB at W12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.466", "spread": "1.0135"}, {"groupId": "OG001", "value": "0.216", "spread": "0.9505"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Parameter: Total score", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.055", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "ANCOVA", "paramType": "Difference of Least Square Means", "paramValue": "0.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "0.42"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Parameter: Symptoms score", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.063", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "ANCOVA", "paramType": "Difference of Least Square Means", "paramValue": "0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.47"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Parameter: Activity limitation score", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.061", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "ANCOVA", "paramType": "Difference of Least Square Means", "paramValue": "0.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.41"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Parameter: Emotional function score", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.156", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "ANCOVA", "paramType": "Difference of Least Square Means", "paramValue": "0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.07", "ciUpperLimit": "0.45"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Parameter: Environmental stimuli score", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.135", "pValueComment": "Hypothesis testing were reported using 2-sided 5% level tests with nominal p-values (i.e., not adjusted for multiplicity).", "statisticalMethod": "ANCOVA", "paramType": "Difference of Least Square Means", "paramValue": "0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.06", "ciUpperLimit": "0.44"}]}, {"type": "SECONDARY", "title": "Serum Concentrations (ng/mL)", "description": "Blood samples (processed to serum) for pharmacokinetic assessments were collected from all patients at baseline prior to first benralizumab administration at Day 1, at the Week 12 visit or the IP discontinuation visit, and at the Week 20 follow-up visit. Serum concentrations of benralizumab were determined using a validated electrochemiluminescent (ECL) immunoassay.", "populationDescription": "The pharmacokinetic (PK) analysis set comprised all patients who received benralizumab and from whom PK blood samples were obtained are assumed not to be affected by factors such as protocol violations. Those patients who had at least 1 quantifiable serum PK observation post first dose were included in the PK analysis dataset.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, Week 12 and Week 20", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "0"}]}], "classes": [{"title": "Pre- 1st dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "All patients had concentration below the limit of quantification (3.86 ng/mL)."}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "999.16", "spread": "95.53"}]}]}, {"title": "Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "59.04", "spread": "317.71"}]}]}]}, {"type": "SECONDARY", "title": "Peripheral Blood Eosinophil Levels", "description": "Peripheral blood eosinophil levels assessments were collected from all patients at baseline prior to first benralizumab administration at Day 1, at the Week 12 visit or the IP discontinuation visit, and at the Week 20 follow-up visit.\n\nChanges at Week 12 (respectively at Week 20) were calculated based on patients with both baseline and Week 12 (respectively Week 20).", "populationDescription": "The safety analysis set comprised all patients who received at least one dose of IP. Patients were classified according to the treatment they actually received. A patient who has on one or several occasions received active treatment was classified as active.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Cells/\u00b5L", "timeFrame": "Baseline, Week 12 and Week 20", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "170", "lowerLimit": "30", "upperLimit": "1060"}, {"groupId": "OG001", "value": "220", "lowerLimit": "40", "upperLimit": "1140"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0", "upperLimit": "110"}, {"groupId": "OG001", "value": "230", "lowerLimit": "30", "upperLimit": "1000"}]}]}, {"title": "Change from baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-170", "lowerLimit": "-1060", "upperLimit": "40"}, {"groupId": "OG001", "value": "10", "lowerLimit": "-710", "upperLimit": "910"}]}]}, {"title": "Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "0", "lowerLimit": "0", "upperLimit": "490"}, {"groupId": "OG001", "value": "210", "lowerLimit": "40", "upperLimit": "1440"}]}]}, {"title": "Change from Baseline at Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-160", "lowerLimit": "-1060", "upperLimit": "130"}, {"groupId": "OG001", "value": "10", "lowerLimit": "-400", "upperLimit": "910"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "AEs, including SAEs, in the on-study period were defined as those with onset between day of the first dose of study treatment and last scheduled follow-up visit, inclusive, up to 20 weeks.", "description": "The safety analysis set comprised all patients who received at least one dose of IP. Patients were classified according to the treatment they actually received. A patient who has on one or several occasions received active treatment was classified as active.\n\nNo subject received wrong dose in the study.", "eventGroups": [{"id": "EG000", "title": "Benralizumab 30 mg Q4W", "description": "Benralizumab administered subcutaneously every 4 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 106, "otherNumAffected": 19, "otherNumAtRisk": 106}, {"id": "EG001", "title": "Placebo", "description": "Placebo administered subcutaneously every 4 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 105, "otherNumAffected": 14, "otherNumAtRisk": 105}], "seriousEvents": [{"term": "Pancytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}, {"term": "Cervix carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 105}]}, {"term": "Colon adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 105}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 106}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 105}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 106}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 105}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 106}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 105}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 106}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 105}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "\u2265 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation."}, "pointOfContact": {"title": "Mitchell Goldman, Global Clinical Leader Benralizumab", "organization": "AstraZeneca Research and Development", "email": "Mitchell.Goldman@astrazeneca.com", "phone": "301 398 0323", "phoneExt": "+1"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}